CombinatoRx (CRXX) Publishes Research Demonstrating Improved Selectivity Through Synergistic Combinations
More News related to CRXX
- CombinatoRx (CRXX) Posts Q3 Loss, Better Y/Y
- CombinatoRx Reports Financial Results for the Third Quarter 2009
- CombinatoRx (CRXX) Reports Positive Efficacy Results From Synavive Trial
- CombinatoRx'S Synavive (CRx-102) Maintains Efficacy Throughout 12 Month Phase 2 Knee OA Extension Trial
- CombinatoRx Abstract Accepted for Oral Presentation at ACR 2009
More News related to Corporate News
- XOMA (XOMA) Falls Modestly Following After-Hours Downgrade
- Morgan Stanley Upgrades CHU to Overweight, Downgrades CHL, CHA to Equal Weight
- Natixis Bleichroeder Downgrades Tenaris S.A. (TS) to Reduce
- Bank of America Downgrades Seneca Foods (SENEB) from Buy
- RBC Downgrades Intrepid Potash (IPI) to Sector Perform
CombinatoRx, Incorporated (NASDAQ: CRXX) \announced the advance online publication by CombinatoRx scientists of an extensive analysis of their discovery screening, scheduled to appear in the August issue of Nature Biotechnology. These new findings provide evidence that multi-target synergistic combinations may be more therapeutically specific than single agents.
By performing a comprehensive synergy analysis across pairs of assays covering six different disease areas and ~100,000 combinations, CombinatoRx scientists have empirically shown that synergistic combinations may yield greater therapeutic selectivity than single drugs. Therapeutic selectivity occurs when a treatment has more beneficial than toxic effect. Additional preclinical analysis by the authors on sample combinations shows that this selectivity results from coordinated context-specific multi-target activity.
Related Categories
Corporate NewsFDA
Stocks Mentioned
+0.25Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
